Swissmedic Approves Roche’s Ronapreve to Treat COVID-19 Patients

By Reuters
Reuters
Reuters
December 27, 2021 Updated: December 27, 2021

ZURICH—Swiss drugs regulator Swissmedic said on Monday it approved Ronapreve, an antibody treatment jointly developed by Roche and Regeneron, to treat COVID-19 patients.

“In this procedure, no data on efficacy against the Omicron variant were submitted,” Swissmedic said in a statement.

The antibody treatment was already authorized for prescription in Switzerland under COVID-19 Ordinance 3 since April 15, Swissmedic said.

Reuters